Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients
Open Access
- 1 February 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (2) , 221-223
- https://doi.org/10.1023/a:1008235801218
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemiaAnnals of Hematology, 1994
- Phase II-Trial of Double-Consolidation Following Intensive Induction Treatment for Improvement of Survival in Elderly Patients with Acute Myeloid LeukemiaLeukemia & Lymphoma, 1994
- Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survivalBritish Journal of Haematology, 1993
- Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemiaBlood, 1992
- Intensive treatment of acute leukemia in adults 70 years of age and olderCancer, 1987
- Phase I–II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemiaMedical and Pediatric Oncology, 1986